Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.

Oncotarget - 19 Aug 2026

Crane Kelly, Bhat K R Seetharam, Grivas P, Necchi Andrea, Bratslavsky Gennady, Shapiro Oleg, Jacob Joseph M, Goldberg Hanan, Sager Rebecca, Ross Jeffery S

Abstract excerpt

Copyright: © 2026 Crane et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. PURPOSE: The discovery of KRAS G12C as a therapeutic target has transformed oncology with the development of specific inhibitors....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Incidence

Share to Microsatellite Instability

Share to Precision Medicine

Share to Proto-Oncogene Proteins p21(ras)

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 42615885
DOI: 10.18632/oncotarget.28912

Genes

KRAS
UBC
TERT
CDKN2A
KDM6A
PBRM1
SETD2
TP53
VHL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.PMID 42615885Read ↗

Molecular Profiling of Bladder Adenocarcinoma Using a National Genomics RepositorySemantic proximity Read ↗

Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.Semantic proximity Read ↗

Beyond driver mutations: exploring the landscape of mutational signatures in adenocarcinomas of the bladder†.Semantic proximity Read ↗

Landscape of KRAS G12C , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS -Mutated CancersSemantic proximity Read ↗

The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.Semantic proximity Read ↗

The germline mutational landscape of genitourinary cancers and its indication for prognosis and riskSemantic proximity Read ↗

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.Semantic proximity Read ↗

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.Semantic proximity Read ↗

Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.Semantic proximity Read ↗

Malfeasance of KRAS mutations in carcinogenesis.Semantic proximity Read ↗

The Abundance of KRAS and RAS Gene Mutations in Cancer.Semantic proximity Read ↗

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.